Adamis Pharmaceuticals Provides Update on Annual Meeting of Stockholders
21 août 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”), convened on Thursday,...
Adamis Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
17 août 2020 16h40 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provided a...
Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19
14 août 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) filing with...
Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
05 août 2020 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has received a letter from the NASDAQ Listing Qualifications Staff (“Nasdaq”)...
Adamis Pharmaceuticals Provides Update on SYMJEPI Products
01 juil. 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’...
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
18 juin 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “Higher naloxone dosing in a...
Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19
15 juin 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license to commercialize Tempol, a novel patented investigational drug...
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
27 mai 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized,...
Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update
18 mai 2020 16h35 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a business...
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA
18 mai 2020 09h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug...